Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients – the study design of the LIBERAL-Trial

CURRENT STATUS: ACCEPTED

Patrick Meybohm  patrick.meybohm@kgu.de
Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt
Corresponding Author
ORCID: 0000-0002-2666-8696

Simone Lindau
Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt

Sascha Treskatsch
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Anesthesiology and Operative Intensive Care Medicine, Campus Charite Mitte and Benjamin Frank

Roland Francis
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Anesthesiology and Operative Intensive Care Medicine, Campus Charite Mitte and Virchow-Klinik

Claudia Spies
Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Anesthesiology and Operative Intensive Care Medicine, Campus Charite Mitte and Virchow-Klinik

Markus Velten
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Bonn

Maria Wittmann
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Bonn

Erdem Gueresir
Department of Neurosurgery, University Hospital Bonn
Christian Stoppe
Department of Intensive Care Medicine, RWTH University Aachen

Ana Kowark
Department of Anesthesiology, RWTH University Aachen

Mark Coburn
Department of Anesthesiology, RWTH University Aachen

Sixten Selleng
Department of Anesthesiology, University Hospital Greifswald

Marcel Baschin
Department of Anesthesiology, University Hospital Greifswald

Gregor Jenichen
Department of Anesthesiology, University Hospital Greifswald

Melanie Meersch
Department of Anaesthesiology, Intensive Care and Pain Therapy, University Hospital Münster

Thomas Ermert
Department of Anaesthesiology, Intensive Care and Pain Therapy, University Hospital Münster

Alexander Zarbock
Department of Anaesthesiology, Intensive Care and Pain Therapy, University Hospital Münster

Peter Kranke
Department of Anaesthesia and Critical Care, University Hospital of Würzburg

Markus Kredel
Department of Anaesthesia and Critical Care, University Hospital of Würzburg

Antonia Helf
Department of Anaesthesia and Critical Care, University Hospital of Würzburg

Rita Laufenberg-Feldmann
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Mainz

Marion Ferner
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Mainz

Eva Wittenmeier
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Mainz

Karl-Heinz Gürtler
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Augsburg

Peter Kienbaum
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Düsseldorf

Marcel Gama de Abreu
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Dresden

Michael Sander
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Giessen-Marburg

Michael Bauer
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Jena

Timo Seyfried
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Regensburg

Matthias Gruenewald
Department of Anaesthesiology and Intensive Care Medicine, University Hospital Schleswig-Holstein, Campus Kiel

Suma Choorapoikayil
Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt

Markus M. Mueller
Institute for Transfusion Medicine and Immunohaematology Frankfurt/ Main, German Red Cross Blood Transfusion Service Baden-Wuerttemberg – Hessen

Erhard Seifried
Institute for Transfusion Medicine and Immunohaematology Frankfurt/ Main, German Red Cross Blood Transfusion Service Baden-Wuerttemberg – Hessen

Oana Brosteanu
Clinical Trial Centre Leipzig, University Leipzig

Holger Bogatsch
Clinical Trial Centre Leipzig, University Leipzig

Dirk Hasenclever
, Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig

Kai Zacharowski
Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt
Abstract

Background: Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia. In healthy and fit individuals, anaemia can be compensated by several mechanisms. Elderly patients, however, have less compensatory mechanisms because of multiple co-morbidities and aging-related decline of functional reserves. The purpose of the study is to evaluate whether elderly surgical patients may benefit from a liberal red blood cell (RBC) transfusion strategy compared to a restrictive transfusion strategy.

Methods: The LIBERAL Trial is a prospective, randomized, multicentre, controlled clinical phase IV trial randomising 2,470 elderly (≥ 70 years) patients undergoing intermediate- or high-risk non-cardiac surgery. Registered patients will be randomised only if Haemoglobin (Hb) reaches ≤ 9 g/dl during surgery or within 3 days after surgery either to the LIBERAL group (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for the post-transfusion Hb level of 9-10.5 g/dl) or the RESTRICTIVE group (transfusion of a single RBC unit when Hb ≤ 7.5 g/dl with a target range for the post-transfusion Hb level of 7.5-9 g/dl). The intervention per patient will be followed until hospital discharge or up to 30 days after surgery, whichever occurs first. The primary efficacy outcome is defined as a composite of all-cause mortality, acute myocardial infarction, acute ischaemic stroke, acute kidney injury (stage III), acute mesenteric ischaemia and acute peripheral vascular ischaemia within 90 days after surgery. Infections requiring iv antibiotics with re-hospitalisation are assessed as important secondary endpoint. The primary endpoint will be analysed by logistic regression adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-risk), and incorporating centres as random effect.

Discussion: The LIBERAL-Trial will evaluate whether a liberal transfusion strategy reduces the occurrence of major adverse events after non-cardiac surgery in the geriatric population compared to a restrictive strategy within 90 days after surgery.
Background

Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia resulting in major events such as myocardial infarction, ischaemic stroke, acute kidney injury, or acute mesenteric ischaemia. In healthy and fit individuals, perioperative anaemia can be compensated by several mechanisms that preserve oxygen transport and oxygen delivery. Therefore, current guidelines recommend a restrictive red blood cell (RBC) transfusion strategy in non-bleeding asymptomatic stable patients.[1, 2]

Several trials revealed that restrictive transfusion is as safe as compared to a liberal strategy. It is noteworthy that the majority of trials only included a limited proportion of elderly patients.[3-7] The compensatory mechanisms, however, are impaired in old and frail patients. Elderly patients have an increased prevalence of cardiovascular comorbidities and decline of functional reserves. In 70 year old patients, e.g. arterial hypertension is present in 75%,[8] diabetes mellitus in 25%,[9] and atrial fibrillation in 10%.[10] Therefore, normal anaemia-related compensatory mechanisms are severely impaired in elderly patients, which may result in greater vulnerability to anaemia-related ischaemic events and perioperative complications.[11, 12]

Carson et al. studied 110 patients with acute coronary syndrome with a mean age of 71 years and found fewer major cardiac events and deaths if red blood cell (RBC) transfusion increased Hb > 10 g/dl compared to a restrictive strategy (10.9% vs. 25.5%).[13] One small trial including 40 patients with hip fracture compared a liberal (RBC transfusion if Hb <10 g/dl) and a restrictive group (if Hb < 8 g/dl), and demonstrated a 2.5-times higher 30-day mortality in the restrictive group.[14] The same group performed a subsequent trial enrolling 2,016 patients older than 50 years of age, who had either a history of or risk factors for cardiovascular disease, and whose Hb level were < 10 g/dl after hip-fracture
surgery. A restrictive strategy (Hb < 8 g/dl) was not superior to a liberal transfusion strategy (Hb < 10 g/dl) regarding mortality rate or inability to walk on 60-days follow-up. [15]

Until now, the available evidence for transfusion criteria is not sufficient for elderly patients. Thus, it is unclear whether current practice and guidelines apply in a geriatric population.[16] Accordingly, major uncertainties exist among clinicians, and current clinical practice is variable. [17, 18] As a result of demographic changes clinicians have to handle a large number of elderly surgical patients with perioperative anaemia and relevant need for RBC transfusion. More than 50% of all RBC transfusions are used in elderly patients in daily practice, and current population dynamics will lead to an increasing demand for RBC transfusions in the old-age patient group.[19]

We hypothesise that a liberal transfusion strategy reduces the occurrence of major adverse events defined as the composite of all-cause mortality and severe ischaemic events within 90 days in elderly patients undergoing non-cardiac surgery compared to a restrictive transfusion strategy.

Methods

The LIBERAL-Trial is a prospective, randomized, open, multicentre, controlled clinical phase IV trial targeting a sample size of 2,470 elderly surgical patients in 15-20 German sites.

Study population A two-step approach will be used (Figure 1, 2): In step I, elderly patients (age ≥70 years) will be registered if scheduled for elective, non-cardiac surgery of intermediate or high risk. Written informed consent is obtained from the patients themselves or from their legally authorised representative/legal guardian.

Risk assessment follows ESC/ESA guidelines: surgery-related risk of cardiovascular death and myocardial infarction.[20] Intermediate risk surgery (30-day risk 1-5%) includes e.g.
intraperitoneal surgery (splenectomy, hiatal hernia), peripheral arterial angioplasty, endovascular aneurysm repair, as well as head and neck, major neurological/orthopaedic (hip and spine), major urological, major gynaecological, intra-thoracic surgery. High risk surgery (30-day risk > 5%) includes e.g. aortic and major vascular, open limb revascularisation, duodeno-pancreatic, liver resection, oesophagectomy, adrenal resection, total cystectomy.

Registered patients will be randomised later only if and as soon as Hb reaches ≤ 9 g/dl during surgery (=day 0) or day 1, 2, or 3 after surgery (step II). If Hb remains > 9 g/dl patients do not enter the main study but vital status (all-cause mortality) will be determined 90 days after surgery.

Exclusion criteria at registration comprise preoperative severe anaemia with Hb level <9 g/dl, chronic kidney injury requiring dialysis, suspected lack of compliance with follow-up procedures, expected death within 3 months, participation in other interventional trials or previous participation in our trial, temporary inability to provide informed consent with absence of a legally authorised representative/ legal guardian, and preoperative autologous blood donation. Additional exclusion criteria at randomisation exclude patients who experienced any component of the composite endpoint or received any allogeneic blood transfusion since registration.

Randomisation and Intervention If Hb intra- or postoperatively reaches ≤ 9 g/dl (despite possible autologous transfusion) determined from blood samples mainly as part of the patient's standard care at any time during surgery (=day 0) or day 1, 2, or 3 after surgery, registered patients will be randomised either to

- LIBERAL group: patients receive a single RBC unit each time Hb reaches ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l), or
· **RESTRICTIVE** group: patients receive a single RBC unit each time Hb reaches $\leq 7.5$ g/dl ($\leq 4.7$ mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).

The target post-transfusion Hb level needs to be reached within 24 hours upon receipt of triggering lab result. The intervention per patient will be followed until hospital discharge or up to 30 days after surgery, whichever occurred first. Physicians will be allowed to refuse to transfuse, or transfuse patients irrespective of the group assignment in exceptional cases, e.g. hypervolaemia, symptomatic anaemia with physiological triggers of anaemic hypoxia, or massive/life-threatening bleeding, but must document the reason(s) in the study eCRF.

Central internet randomisation at the Clinical Trial Centre Leipzig uses block randomisation with variable block length stratified by centre. For urgent randomisation or in case of internet unavailability randomisation can be performed using sealed envelopes. Envelope randomisations will be checked during on-site monitoring.

All trial patients will receive standard perioperative care. The patients in both groups will not be exposed to additional risk since transfusion-strategy studies almost showed the same results. Hb transfusion thresholds used in previous studies varied from 7 to 10 g/dl for the restrictive and from 9 to 13 g/dl for the liberal group, respectively.[5, 6, 15] In addition RBC transfusion is the main treatment option for anaemia due to surgical blood loss. All patients benefit from intensive monitoring and consequently early detection of any decrease of Hb-level.

**Trial Drug**

The strategies under evaluation use different Hb levels as trigger for RBC transfusions and aim at different target ranges of Hb levels to be maintained. The trial drug will be manufactured and used as in standard care. Only commercially available approved RBC
units will be used within this clinical trial and a list of these approved RBCs is online available.[21] RBCs are provided by the local blood bank according to clinical routine considering the requirements of §63i AMG. This will assure the participants’ safety, the traceability and identification of the RBCs given. Therefore, a special labelling of the RBCs for the trial according to § 42 AMG and § 5 GCP-V is not necessary.

Endpoints

The primary efficacy outcome is a binary composite of death from any cause and anaemia-associated, ischaemic events (defined as acute myocardial infarction, acute stroke, acute kidney injury stage III, acute mesenteric ischaemia, acute peripheral vascular ischaemia) within 90 days after surgery. With the proposed composite, we assess relevant anaemia-associated ischaemic events encompassing five different organs (brain, heart, kidney, gut, limbs) where the assigned Hb level/transfusion strategy will likely have an effect.

The primary efficacy outcome is defined as a composite of (within 90 days after surgery):

I. All-cause mortality is defined as death from any cause.

II. Acute myocardial infarction confirmed by a cardiologist.

III. Acute ischaemic stroke confirmed by a neurologist.

IV. Acute kidney injury (stage III) is defined according to the Kidney Disease Improving Global Outcomes criteria: Increase of plasma creatinine level ≥ 3 times within a time window of 7 days or initiation of renal replacement therapy.[22]

(Serum creatinine concentration will be measured at least every 7 days until hospital discharge. Urine output criteria will not be used to define acute kidney injury because most of hospital do not mandate hourly urine output measurements on all patients, and because of the likelihood of inaccurate measurement in the substantial number of patients without urinary catheters.)

V. Acute mesenteric ischaemia is defined as ischaemia confirmed by intervention
VI. Acute peripheral vascular ischaemia is defined as a new non-thrombotic compromised circulation in a limb confirmed by angiography and/or leading to surgery.

After hospital discharge, events will only be considered as present if they lead to hospital re-admission or death. Direct transfer to another hospital will not be defined as re-admission.

Infection was not included into the composite endpoint since more transfusions may reduce ischaemic events, but might show a counter effect increasing the infection risk.

Secondary endpoints Secondary outcome measures are the following:
· The occurrence of any individual component of the composite at hospital discharge, at 90 days, and 1 year after surgery.
· Proportion of patients receiving RBC transfusion and the number of units transfused.
· Total length of stay in the intensive care unit and in hospital from randomisation to discharge (for strategy comparison); in addition, total length of stay in the intensive care unit and in hospital from admission to discharge will be used for descriptive purposes.
· The occurrence of acute kidney injury (stage I or II) defined according to the Kidney Disease Improving Global Outcomes criteria[22] (stage I: increase of plasma creatinine level $\geq$ 1.5-1.9 times baseline or $\geq$ 0.3 mg/dl within 48 hours; stage II: increase of plasma creatinine level $\geq$ 2-2.9 times baseline within a time window of 7 days) during the initial hospital stay.
· Time to (first) infection (infection requiring therapeutic intravenous antibiotic treatment (pneumonia, wound infection, sepsis, central line associated blood stream infection[22-24])) during the initial hospital stay or leading to hospital re-admission within 90 days after surgery.
· Time to (first) re-hospitalisation within 90 days.
· Functional status (assessed by Barthel Index [25, 26] by telephone questionnaire).

· Health-related quality of life (assessed by EuroQol EQ-5D [27, 28] and 12-item World Health Organisation Disability Assessment Schedule WHODAS 2.0 [29] by telephone questionnaire).

Sample size considerations

For the primary endpoint, we expect an overall composite complication rate (OCCR) of about 25% at 90 days after surgery. This guestimate is based on a subgroup of elderly patients included in a large observational study in the field of Patient Blood Management[30], which reported most of the endpoint components, and is also based on the assumption that about 25-40% of registered patients will be randomised.

The effect size to be detected is set to an odds ratio of OR=0.765. The available evidence on treatment differences from randomised trials concerning the old age group is sparse and inconsistent. Therefore, we choose an effect size, which is relevant from a clinical perspective. Assuming an OCCR of 25%, an odds ratio of OR=0.765, corresponding to a 5% reduction in OCCR from 27.5% to 22.5% or risk reduction of 18%, would justify switching to the liberal transfusion strategy.

The target sample size is N= 2,470 randomised patients. Randomisation of 2 x 1,176=2,352 patients is required using a two-sided significance level of 5% and requiring power of 80% for a test of the null-hypothesis OR=1 versus OR=0.765 based on the normal approximation to log(OR). We allow for a dropout rate of up to 5%.

Statistical analysis

The full analysis set for the primary efficacy analysis will be as close as possible to the ideal implied by the intention-to-treat principle and includes all randomised subjects. A secondary per-protocol analysis of the primary outcome will be performed in all patients without major protocol violations.
Most endpoints will be analysed with scale-appropriate generalised linear mixed models adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-risk), and incorporating centres as random effect. Further baseline clinical variables may be entered in secondary analyses.

For the primary endpoint, logistic regression will be used to estimate the treatment effect on the odds ratio scale with two-sided 95% confidence intervals provided. Secondarily, also point estimates and confidence intervals for the rate difference and the relative risk will be provided. The test of the null hypothesis that the odds ratio concerning the composite endpoint is equal to one will be tested using the Wald statistic for the coefficient of the treatment effect in the logistic regression.

Interim analyses

One formal unblinded interim analysis is scheduled after about 1,450 patients with 90-day endpoint information in order to detect early superiority. This interim analysis will use a significance level of alpha=0.001 such that the final analysis does not require adjusting for multiple testing. With this interim analysis, we will have 80% power to detect an odds ratio of 0.6, which corresponds to an OCCR difference in the order of 10%.

If the interim analysis turns out significant, the trial will be stopped, unless the Data Monitoring Safety Board (DMSB) recommends otherwise. The responsible study biometrician will perform the formal interim analysis, write a strictly confidential report and discuss the results exclusively with the Data Monitoring Safety Board. If the DSMC recommends continuing with the trial, the Sponsor, the steering committee, the investigators, and the study team will only receive the information that the interim analysis for early superiority was performed and discussed with the DSMC and that the trial continues. All respective documents and analysis scripts are kept on a dedicated file system to which only the biometrician and his assistant have access rights.
Planned exploratory sub-group analyses

We hypothesise that the benefit from a liberal transfusion strategy increases with declining anaemia compensatory capacity.

We will therefore perform exploratory subgroup analyses by

- Age (< 80 versus ≥ 80 years),
- Gender (male/female),
- American Society of Anaesthesiology Physical Status classification,[31]
- presence of cancer (y/n),
- ischaemic heart disease (y/n),
- heart failure (y/n),
- peripheral vascular disease (y/n),
- previous stroke (y/n),

Any resulting hypothesis requires confirmation in independent data.

Analysis in the larger set of all registered patients

We collect course of Hb levels during surgery (= day 0) or day 1, 2, 3 after surgery and the vital status at day 90 (all-cause mortality) for all registered patients.

The prognostic value of delta Hb (difference pre-op Hb and Hb on day three) and Barthel index on short term mortality will be analysed adding these factors to the generalised linear mixed model specified above.

Clinical study monitoring On-site monitoring follows a risk-adapted approach.[32, 33] Pre-study, initiation, regular, and closeout visits will be performed in all centres. The first regular visit takes place after discharge or day 30 after surgery of the first 3 randomized patients, the following visits will be performed after the discharge of additionally 15 more patients, but at least once a year. The intention of the visits will be to achieve high protocol compliance and data quality, as well as to ensure patients’ safety and rights.
Central monitoring will include a timely query management process based on consistency and plausibility checks combined with a dunning process for missing documentation. In addition, the trial biometrician performs statistical monitoring regularly in order to detect general and centre-specific problems in key study processes. Quality endpoints include accrual rate, rate of dropouts and protocol violations, promptness of randomisation when anaemia emerges, adherence to the assigned transfusion strategies, as well as timeliness of documentation.

Discussion

The transfusion of allogenic RBC units is the standard procedure to treat peri- and postoperative severe anaemia. More than 50% of all RBC transfusions are used in old and frail patients, and current population dynamics in most developed countries will lead to an increasing demand for RBC transfusions.[19] Elderly patients have an increased prevalence of cardiovascular comorbidities and decline of functional reserves. Therefore, anaemia-related compensatory mechanisms are severely impaired in elderly patients, which may result in greater vulnerability to anaemia-related ischaemic events and perioperative complications.[11, 12]

Here, the LIBERAL-Trial will provide a definite answer for this patient group whether a liberal transfusion strategy reduces the occurrence of major adverse events defined as the composite of all-cause mortality and severe ischaemic events within 90 days after non-cardiac surgery compared to a restrictive strategy.

Potential limitations might refer to cross-over between groups, needing to 'register' a large number of patients, lack of recruiting, and drop-out due to various protocol violations.

Declarations
Trial Status

Study protocol (V3.0) was finalised at 17th of October 2017. This trial was registered at https://clinicaltrials.gov (identifier: NCT03369210) at 12th of November 2017. Recruitment and enrolment of the patients started in January 2018, more than 200 patients have been registered and more than 100 randomised so far. The planned recruitment lasts 36 months.

List of abbreviations

Hb, haemoglobin; RBC, red blood cell; AMG, Arzneimittelgesetz; BGA, blood gas analysis; eCRF, electronic case report form; OCCR, overall composite complication rate; GCP, Good clinical practice

Ethics Study protocol V3.0 (EudraCT-Nr 2016-004446-29), patient information, and informed consent were approved by the Ethics Committee of the University of Frankfurt (Ref: 139/17F) and of all participating centres. At the same time the study documents have been approved by the responsible federal authority (Paul-Ehrlich-Institute) according to the requirements of GCP-V § 7. Each patient must give written informed consent to participate in the study.

Consent for publication

Not applicable

Availability of data and material

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request after the end of the trial.

A fulfilled SPIRIT 2013 Checklist is available as an additional file.

Competing interests

M.M and E.S. work for the German Red Cross, deliver RBC units and may have a financial competing interest.
All other authors declare that they have no competing interests.

Funding

This work is supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; grant no. ME 3559/3-1) who had / will not have any impact in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Authors contributions

All authors have substantially contributed to the interpretation of current specific knowledge, which resulted in the conception and design of the present trial. PM, KZ, SC, MMM, ES, and DH are investigators of the present trial and participated in the acquisition of funding. PM, SL, ST, RF, CS, MV, MW, EG, CS, AK, MC, SS, MB, GJ, MM, TE, AZ, PK, MK, AH, RLF, MF, EW, KHG, PK, MGA, MS, MB, TS, and MG contribute to the collection of data. OB and HB are responsible for project management. DH wrote the statistical methods. All authors have been involved in drafting the manuscript or revising it critically for important intellectual content, and approved the final manuscript.

Acknowledgement

The LIBERAL collaboration group will be listed as an author, and the names of the individual members of the group will be searchable through their individual PubMed records:

Medizinische Universität Wien: David Baron (david.baron@meduniwien.ac.at)

RWTH Aachen

Oliver Grottke (ogrottke@ukaachen.de)

Aileen Hill (ahill@ukaachen.de)

Julia Van Waesberghe (jvanwaesberg@ukaachen.de)
Sebastian Ziemann (sziemann@ukaachen.de)
Markus Tingart (mtingart@ukaachen.de)
Julius van Essen (jvanessen@ukaachen.de)
University Hospital Augsburg
Oliver Spring (oliver.spring@klinikum-augsburg.de)
Raphael Pirzer (raphael.pirzer@klinikum-augsburg.de)
Ulrich Jaschinski (Ulrich.Jaschinski@klinikum-augsburg.de)
Axel R Heller (axel.heller@klinikum-augsburg.de)
Charite Berlin
Martin Ertmer (martin.ertmer@charite.de)
Elke Falk (Elke.Falk@charite.de)
Philipp Pickerodt (philipp-pickerodt@charite.de)
Alexander Schiemann (alexander.schiemann@charite.de)
Katrin Schmidt (kat.schmidt@charite.de)
Sascha Tafelski (sascha.tafelski@charite.de)
Ralf-Felix Trauzeddel (ralf-felix.trauzeddel@charite.de)
Carsten Perka (carsten.perka@charite.de)
University Hospital Bonn
Heide Ehrentraut (heidi.ehrentraut@ukbonn.de)
Louise Fingerhut (louise.fingerhut@ukbonn.de)
Andreas Hopf (andreas.hopf@ukbonn.de)
Vera Guttenthaler (vera.guttenthaler@ukbonn.de)
Claudia Neumann (claudia.neumann@ukbonn.de)
Isabelle Osberghaus (isabelle.osberghaus@ukbonn.de)
Patrick Schuss (patrick.schuss@ukbonn.de)
Anja Winkler (anja.winkler@ukbonn.de)
Hendrik Kohlhof (Hendrik.Kohlhof@ukbonn.de)
Dieter C. Wirtz (dieter.wirtz@ukbonn.de)

University Hospital Duesseldorf
Robert Kalb (Robert.Kalb@med.uni-duesseldorf.de)
Jonas Hinterberg (Jonas.Hinterberg@med.uni-duesseldorf.de)
Maximilian Schäfer (Maximilian.Schaefer@med.uni-duesseldorf.de)

University Hospital Dresden
Thea Koch (Thea.Koch@uniklinikum-dresden.de)

University Hospital Frankfurt
Florian Piekarski (florian.piekarski@kgu.de)
Linda Tanner (linda.tanner@kgu.de)
Kira Berg (kira.berg@kgu.de)
Carolin Wiedenbeck (carolin.wiedenbeck@kgu.de)
Isabell Maushagen (isabell.maushagen@kgu.de)
Daniela Zeisset (daniela.zeisset@kgu.de)
Christoph Fuellenbach (christoph.fuellenbach@kgu.de)
Sabine Westphal (sabine.westphal@kgu.de)
Sophia Pfeiffer (sophia.pfeiffer@gmx.net)
Andreas Schnitzbauer (andreas.schnitzbauer@kgu.de)
Ingo Marzi (ingo.marzi@kgu.de)
Andreas Becker (andreas.becker@kgu.de)
Shahram Ghanaati (shahram.ghanaati@kgu.de)
Thomas Schmitz-Rixen (schmitz-rixen@em.uni-frankfurt.de)
Verena Brixner (v.brixner@blutspende.de)
University Hospital Schleswig-Holstein, Campus Kiel
Corinna Buchholz (corinna.buchholz@uksh.de)
Birte Heller (birte.heller@uksh.de)
Jochen Renner (jochen.renner@uksh.de)
Nina Schulz-Ruhtenberg (nina.schulz-ruhtenberg@uksh.de)
Gunnar Elke (gunnar.elke@kgu.de)

Universitätsmedizin Mainz
Susanne Fischer (susanne.fischer@unimedizin-mainz.de)
Sabine Hofbauer (sabine.hofbauer@unimedizin-mainz.de)
Peter Straub (peter.straub@unimedizin-mainz.de)
Sophie Zimmer (szimmer@students.uni-mainz.de)

University Hospital Muenster
Mira Küllmar (kuellmar@anit.uni-muenster.de)
Nadine Rosenow (rosenown@anit.uni-muenster.de)
Christina Massoth (christina.massoth@anit.uni-muenster.de)
Raphael Weiss (r_weiss@anit.uni-muenster.de)

University Hospital Regensburg
Diane Bitzinger (diane.bitzinger@klinik.uni-regensburg.de)
Karin Pfister (karin.pfister@ukr.de)

University Hospital Würzburg
Ines Guzman (guzman_i@ukw.de)
Eva-Maria Kranke (kranke_e@ukw.de)
Norbert Roewer (an_direktion@ukw.de)
Achim Woeckel (woeckel_a@ukw.de)

References
1. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al: Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA 2016, 316:2025-2035.

2. Padhi S, Kemmis-Betty S, Rajesh S, Hill J, Murphy MF, Guideline Development G: Blood transfusion: summary of NICE guidance. BMJ 2015, 351:h5832.

3. Carson JL, Sieber F, Cook DR, Hoover DR, Noveck H, Chaitman BR, et al: Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 2015, 385:1183-1189.

4. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340:409-417.

5. Holst LB, Haase N, Wetterslev J, Wernerman J, Guttormsen AB, Karlsson S, et al: Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014, 371:1381-1391.

6. Murphy GJ, Pike K, Rogers CA, Wordsworth S, Stokes EA, Angelini GD, et al: Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015, 372:997-1008.

7. Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, et al: Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013, 368:11-21.

8. Neuhauser HK, Adler C, Rosario AS, Diederichs C, Ellert U: Hypertension prevalence, awareness, treatment and control in Germany 1998 and 2008-11. J Hum Hypertens 2015, 29:247-253.

9. Sue Kirkman M, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, et al: Diabetes in older adults: a consensus report. J Am Geriatr Soc 2012, 60:2342-2356.
10. Lubitz SA, Bauer KA, Benjamin EJ, Besdine RW, Forman DE, Gurol ME, et al: Stroke prevention in atrial fibrillation in older adults: existing knowledge gaps and areas for innovation: a summary of an American Federation for Aging research seminar. J Am Geriatr Soc 2013, 61:1798-1803.

11. Goodnough LT, Schrier SL: Evaluation and management of anemia in the elderly. Am J Hematol 2014, 89:88-96.

12. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al: Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-156.

13. Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, et al: Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 2013, 165:964-971 e961.

14. Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA, et al: A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion 1998, 38:522-529.

15. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al: Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011, 365:2453-2462.

16. Simon GI, Craswell A, Thom O, FungYL: Outcomes of restrictive versus liberal transfusion strategies in older adults from nine randomised controlled trials: a systematic review and meta-analysis. Lancet Haematol 2017, 4:e465-e474.

17. Frank SM, Savage WJ, Rothschild JA, Rivers RJ, Ness PM, Paul SL, et al: Variability in blood and blood component utilization as assessed by an anesthesia information management system. Anesthesiology 2012, 117:99-106.

18. Gombotz H, Rehak PH, Shander A, Hofmann A: The second Austrian benchmark study for blood use in elective surgery: results and practice change. Transfusion 2014, 54:2646-
2657.

19. Greinacher A, Fendrich K, Brzenska R, Kiefel V, Hoffmann W: Implications of demographics on future blood supply: a population-based cross-sectional study. Transfusion 2011, 51:702-709.

20. Authors/Task Force M, Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, et al: 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J 2014, 35:2383-2431.

21. [http://www.pei.de/DE/arzneimittel/blutprodukte/blutkomponenten-zur-transfusion/erythrozytenkonzentrate/erythrozytenkonzentrate-node.html]

22. Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Pelosi P, et al: Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol 2015, 32:88-105.

23. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228.

24. Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Kuhn L, et al: Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014, 311:1317-1326.

25. Collin C, Wade DT, Davies S, Horne V: The Barthel ADL Index: a reliability study. Int Disabil Stud 1988, 10:61-63.

26. Barthel Index Hamburger Manual
27. Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343.

28. Tidermark J, Bergstrom G: Responsiveness of the EuroQol (EQ-5D) and the Nottingham Health Profile (NHP) in elderly patients with femoral neck fractures. Qual Life Res 2007, 16:321-330.

29. Xenouli G, Xenoulis K, Sarafis P, Niakas D, Alexopoulos EC: Validation of the World Health Organization Disability Assessment Schedule (WHO-DAS II) in Greek and its added value to the Short Form 36 (SF-36) in a sample of people with or without disabilities. Disabil Health J 2016, 9:518-523.

30. Meybohm P, Herrmann E, Steinbicker AU, Wittmann M, Gruenewald M, Fischer D, et al: Patient Blood Management is Associated With a Substantial Reduction of Red Blood Cell Utilization and Safe for Patient’s Outcome. A Prospective, Multicenter Cohort Study With a Noninferiority Design. Ann Surg 2016, 264:203-211.

31. Hackett NJ, De Oliveira GS, Jain UK, Kim JY: ASA class is a reliable independent predictor of medical complications and mortality following surgery. Int J Surg 2015.

32. Brosteanu O, Houben P, Ihrig K, Ohmann C, Paulus U, Pfistner B, et al: Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials. Clin Trials 2009, 6:585-596.

33. Brosteanu O, Schwarz G, Houben P, Paulus U, Strenge-Hesse A, Zettelmeyer U, et al: Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study. Clin Trials 2017, 14:584-596.

Figures
| Examinations                                                                 | Screening | Surgery | Observation before randomisation | Rando-misation¹ | Intervention/ Observation after randomisation | Discharge | Day 90 after surgery | Follow up 1 year after surgery |
|----------------------------------------------------------------------------|-----------|---------|----------------------------------|----------------|-----------------------------------------------|-----------|---------------------|-------------------------------|
| Visits                                                                      | V1        | V2      | V3                               | V4             | V5                                            | V6        | V7                  | V8                           |
| Inclusion criteria                                                         | X         |         |                                  |                |                                               |           |                     |                               |
| Exclusion criteria                                                         | X         |         |                                  |                |                                               |           |                     |                               |
| Informed consent                                                           | X         |         |                                  |                |                                               |           |                     |                               |
| Registration                                                                |           |         |                                  |                |                                               |           |                     |                               |
| Demographic data, medical history                                          | X         |         |                                  |                |                                               |           |                     |                               |
| Physical examination                                                       | X         |         |                                  |                |                                               |           |                     |                               |
| Laboratory (haemoglobin, creatinine)                                        | X         |         | X¹,b                            |                |                                               |           |                     |                               |
| Surgery                                                                    |           |         |                                  |                |                                               |           |                     |                               |
| Functional status (Barthel index)                                          | X         |         |                                  |                |                                               |           |                     |                               |
| Health-related quality of life                                              |           |         |                                  |                |                                               |           |                     |                               |
| Randomisation                                                              |           |         |                                  |                |                                               |           |                     |                               |
| Intervention ² incl. time and number of transfused RBC units               |           |         |                                  |                |                                               |           |                     |                               |
| Anaemia-associated ischaemic events (components of primary endpoint)       |           |         |                                  |                |                                               |           |                     |                               |
| ICU and hospital stay                                                       |           |         |                                  |                |                                               |           |                     |                               |
| Infection requiring i.v. antibiotics                                        |           |         |                                  |                |                                               |           |                     |                               |
| Re-hospitalisation for any cause                                           |           |         |                                  |                |                                               |           |                     |                               |
| Acute kidney injury stage 1-II                                              |           |         |                                  |                |                                               |           |                     |                               |
| All-cause mortality                                                        |           |         |                                  |                |                                               |           |                     | X                             |
| AE/SAE-Monitoring                                                          |           |         |                                  |                |                                               |           |                     |                               |

¹ Randomisation is not mentioned for specific time points.
² Interventions may vary depending on the specific study design.
³ Data collection times may vary for specific assessments.
Figure 1

Figure 1 Schedule of Assessments and Procedures X: assessments for all registered patients / closed circle: additional assessments for randomised patients

1 Randomisation: as soon as haemoglobin ≤9 g/dl (BGA measurement) during surgery (=day 0) or day 1, 2, or 3 after surgery, registered consenting patients will be randomised. Re-evaluation of inclusion-/exclusion criteria before randomisation only refers to obvious occurrence of any component of the composite endpoint and any allogeneic blood transfusion after registration (chapter 4.2.2.). No specified diagnostics are scheduled. 2a Haemoglobin levels will be determined from blood samples (primarily BGA measurement mainly as part of the patient’s usual care) at least daily before randomisation. 2b Mild drop of haemoglobin < 9 g/dl due to induction of anaesthesia before skin incision is permitted and not an exclusion criteria. 2c Haemoglobin levels will be determined from blood samples (primarily BGA measurement mainly as part of the patient’s usual care) at any time during or after randomisation until hospital discharge (up to 30 days after surgery; at least every 3 days), and after each transfused unit.

Creatinine levels will be determined as part of the patient’s usual care at any time during or after randomisation until hospital discharge (or up to 30 days after surgery; at least every 7 days). 3 Intra-/Postoperative Intervention: Duration of intervention per patient: from intra-/postoperative randomisation until hospital discharge or 30 days after surgery, whichever occurs first. Physicians will be instructed to transfuse RBC units each time haemoglobin is lower than the randomised threshold and as soon as possible. The randomised target post-transfusion Hb level needs to be reached each time within 24 hours upon receipt of lab result at the latest.
Figure 2 Study intervention Hb levels will be determined from BGA blood samples (*) mainly as part of the patient’s usual care at any time during or after surgery (up to 30 days after surgery; at least every 3 days), and after each transfused unit. Consenting patients will be registered (Step I) and will be randomised as soon as Hb falls ≤9 g/dl during surgery (=day 0) or day 1, 2, or 3 after surgery.

Physicians will be instructed to transfuse RBC units each time Hb is lower than the defined threshold and as soon as possible. The target post-transfusion Hb level needs to be reached within 24 hours upon receipt of lab result at latest. The intervention per patient will be followed until hospital discharge or up to 30 days, whichever occurred first, comparable to recent large trials.[5-7, 15] In case of any massive or life-threatening bleeding, the single-unit policy should be paused.

Supplementary Files
This is a list of supplementary files associated with the primary manuscript. Click to download.

SPIRIT-Checklist Liberal_details.doc